Aagami Technology Licensing Presentation

May 2015

Realizing Possibilities, Together

Technology Licensing Services

Meet us at:

Lifesciences Catalyst2

Aagami, Inc.

A lifesciences consulting firm based in the suburbs of Chicago offers

For Universities, Global Biotech, Pharmaceutical , Medical Devices and Consumer Health products companies, in their initiatives with India, Asia and Emerging Markets.

Technology Licensing ServicesStrategic Consulting ServicesBusiness & Market Research Services


Needs of University Tech Transfer Offices

Reach in the Investors’ world

Access to Global Commercial Network

Ability to speak “Investors’ language”

Commercial Perspective on technology

‘Out of box’ thinking to widen market applications

Ability to talk “Business’ language”

Realistic Evaluation of commercial potential


Technology Licensing Organizations (TLO) Concept

TLOs – An emerging business model

Complements/supplements Tech Transfer offices

Licensing is the core business (‘raison d'être’)

Have access to panel of experts

Operate in the commercial markets

Participate in trade shows and conferences

Honed skills with multiple institutions/assignments

Bring ‘out of the Box’ thinking


Aagami TLO Services

Consolidate Industry demand

Consolidate available technologies

Evaluate Technologies to fit the demand

Evaluate Commercial Potential

Promote specific technologies

Generate focused marketing brochures

Broadcast to specific (relevant) companies

Exchange information with the interested

Help and support finalizing Licensing agreements


Aagami TLO Framework

Wide-ranging Experience in the Biotech, Pharmaceutical and Medical Device industry, Infotech, Alternate Energy

Global Experience in Start-Ups, Licensing, M&As, Forming JVs and Investing

Good understanding of the ways of working (business culture) in multiple geographies such as US, Europe, Japan, India, and Israel

Extensive Global network including the top 200 Indian companies at CXO levels


Sample list of Demand ‘Sweet Spots’ Novel Delivery Technologies

New Chemical Entities (NCE), Peptides, Biologics, Biosimilars, Vaccines in Therapeutic areas

Pain and Inflammation,

Diabetes and Metabolic disorders,

Anti-infective,

Oncology

Biomarkers for Oncology and Metabolic disorders

Synthesis Technologies for

Peptide,

Biosimilars and

Monoclonal Antibodies,


Sample list of ‘sweet spots’ …contd

Pharmaceutical Technologies for

Analytical characterization of large molecules,

Cost-cutting in formulation and/or API manufacturing

for difficult to manufacture generics

Manufacturing Technologies in forgings and other automotive components

Novel Technologies in Solar energy, LEDs, Water purification

Technologies with space applications

9

Sample list of Aagami Clients

USA

CreAgri CA

New Heaven Pharma CT

Advangene IL

Loyola Univ. Chicago IL

OncBioMune LA

Dow Chemicals MI

ScyFIX MN

Penwest Corp. NY

DesignMedix OR

PLx TX

InternationalPhosphagenics Australia

PeptiSyntha Belgium

DelMar Pharma Canada

Affitech Denmark

Pieris Germany

Merus Holland

Venus Remedies India

Opsona Ireland

Toppan Japan

Otago University New Zealand

Lifesciences Catalyst

Aagami has completed over 100 assignments for more than 50 clients in the last 12+ years.


Sample of Aagami contacts in India

We are connected at CXO Level of TOP 100 Lifesciences companies in India. Some of the popular names are below.

Biocon Intas Sun Pharma

Cadila Lupin Themis

Cipla MicroLabs Torrent Pharma

Dr Reddys Piramal USV

Glenmark Reliance Wockhardt

Hetero Drugs Strides Zydus


Aagami brings

Deep Understanding of business and socio-cultural differences in ways of working

Extensive network with Top LifeSciences companies at CXO levels

Global Deal experience mainly with Western, Japanese and Indian industry

Aagami Partners bring value of combined experience of over 150 years.

Focus on client needs, objectives, success and work as an extension of client’s own team.


Our Consulting Approach

Setup

• Understand and capture important details about the asset/technology

• Prepare ‘Elevator Pitch’ (EP) customized to specific business culture

• Identify relevant companies from our database and resources

Prospect

• Broadcast EP to Relevant Companies

• Follow-up with phone calls and emails

• Coordinate CDAs with interested Companies

• Supply further info through emails

• Organize conference calls for clarifications

Finalize

• Organize Road show

• Manage appointments with right executives

• Coordinate the logistics of the road show

• Advise on structuring the deal

• Support in negotiations (most critical)

Why Work with Aagami Approach

Working with Aagami

• Verified and Reliable Partner

• Leverage Deep Connections of Aagami

• Faster Results

• Significant Savings of time and effort (=cost)

• Deal experience and existing relationships with Industry

• Proven track record

Doing it Yourself (DIY)

• Spend Considerable more time, valuable resource and money

• Opportunity Cost

• Uncertainty on Results

• Less understanding of market dynamics

• No Existing Relationship with companies in Target Geographies

© Aagami, Inc. 2015 | All rights reserved | www.aagami.com13


Working with Aagami- Engagement Model

Dedicated Teamwork (40-80 Hours/month)

Small monthly ‘binding’ fee for first 6 months

Success fee based on the modified Lehman’s formula

Aagami’s prime focus is CLIENT SUCCESS as that's how we Succeed


Aagami Leadership Team 1 of 2

Dinesh Jain – Founder CEO

• A business leader in Science and technology industry since 1984 with global experience in starting and managing several technology companies. Has held positions of CEO, President, Vice President. Is a prolific entrepreneur. Has executed several dozen international deals across 4 continents. He is a regular speaker in International conference son Life Sciences Business with India, and also on board of several consulting and research companies

Dr. Mahendra Shah, Ph D – Scientific & Business

• A veteran Scientific leader in Bio-Pharmaceutical field since 1968 . After his PhD, he has worked with some of the top notch companies like Bristol, Squibb, Schering, Lyphomed, Fujisawa, EJ Financials, First Horizon, NextWave. Mahendra is an active Investor in BioPharmaceutical field and is on the Board of several companies across the country.

Michael S. Rosen - Business

• A Senior executive and entrepreneur working globally since 1974. Managed 3 multinational pharma and agro-science companies working in Europe, Latin America, Japan, Canada, Asia and Israel. CEO experience starting and growing several biotech and medical device companies in the U.S. and Europe, raising more than $50 million in equity and taking 1 company public. Economic development expertise creating and expanding vibrant science parks and life-science ecosystems as public-private partnerships


Aagami Leadership Team 2 of 2

Dr. Aman Ahuja, M.D., F.P.M., F.R.C.A. – Medical

• A specialist pain medicine physician and consultant at the North Queensland, Australia. MD Anaesthesia from India, Fellow of Royal College of Anaesthetists, Ireland, Masters in Pain Medicine from UK, Fellow of Tess Cramond Multidisciplinary Pain Centre, Australia; Dr. Ahuja has focus on clinical practice, research and advancing rational therapies for a diverse range of conditions. His current interests include studying the expanding role of radiofrequency in field of Pain Medicine. Dr. Ahuja uses a compassionate and multidisciplinary approach in his well known practice as a Pain Specialist and Anesthetist.

Dr. Shridhar Andurkar, Ph D – Scientific

• Chair and Associate Professor of Pharmaceutical sciences at Midwestern University, Chicago College of Pharmacy, is a Ph D from Auburn University in Medicinal Chemistry, Conducted postdoctoral research at the University of Houston. Dr. Andurkar has published numerous papers and made several presentations in this field. He holds a US patent in the area of anticonvulsant drugs and is on the advisory boards of several companies.

Nancy Chew - Regulatory

• A serial entrepreneur, veteran business leader, biochemist and Pharmacologist by education, Regulatory expert, Several top honors & award winner and Advisor to numerous Life Sciences companies. Nancy's accomplishments and achievements of over 39 years would take several pages to detail.


Aagami Associate Partners Dr. Hemant Sabharwal M.D., Ph.D. – Founder - Laktobiotics

• 15 years of extensive global experience in the Academia and Pharma Industry. Lived and worked in the Middle East, Egypt, Scandinavia, India, and the US. He is also Adjunct Faculty in Department of Medical Microbiology and Immunology, Streptococcal vaccine development, Rockefeller University, New York, NY. To his credit, he has more than 20 publications in peer reviewed Medical and Scientific journals. In the past, he has worked with prestigious institutions such as Institute for Cancer Prevention, NY, Mount Sinai Medical Center, NY, Lund University, Sweden, MonoCarb AB, Sweden, BioCarb AB, Sweden

Anant Kataria – Founder Partner, Sagacious Research• Anant's expertise lies in supporting Patent Practitioners/Consultants, Patent Licensing Firms/Executives, Law firms

in US and Europe by providing a cost-effective back-end team for all their patent related needs. His past work experience is a blend of Intellectual Property Research (IP) in various technical domains and R&D in Automobile Industry.

Vyom Shah, Founder, Phronesis Strategies• Vyom has worked with companies such as PwC and TCS. With 9+ years of experience, he has extensively worked

on several consulting and research cases including NPV valuations across diverse verticals and has served clients ranging from Fortune 500 companies to SMEs, supporting end-to-end engagement lifecycle. He holds an MBA from Lancaster University Management School, UK, specialising in Strategy and Management Consulting and is a qualified Chartered Accountant.

Faiz Wahid - Co-founder, pManifold Research and Consulting• Faiz started pManifold in 2010 focusing on research, consulting and stakeholder engagement services. Under his

leadership the firm has conducted over 10000+ primary customer interviews for various cross sector companies. He holds an MBA from HEC Paris and was an international scholar at the Darden School of Business of the University of Virginia. He also holds a masters in engineering from BITS Pilani and bachelors in engineering from VNIT Nagpur.

Offerings in Market/ Business Research

Competitive Landscape Assessments

Analysis of Portfolio and Opportunities identification

Price Discovery Research

Due Diligence

IP and Regulatory Research

Financial Modeling, NPV valuations

New Market Entry strategy

Market development strategy

18 Lifesciences Catalyst

Research Methodology

Study/ Research

• Primary

• Interviews with different stakeholders in the Value chain including opinion leaders, vendors and customers

• Proceedings of Industry events, press conferences and workshops

• Surveys /studies

• Secondary

• Company websites, social media, blogs, forums and groups

• Business directories and databases

• Online and offline libraries and government data

• Economic and Demographic information, Census

• Case studies, Reference Customers, vendors, and associations

Analysis

• Qualitative

• Policy and Regulatory environment

• Competitive Landscape Assessment (CLA)

• Business Analysis, Industry Analysis

• Trends & Drivers,

• Challenges and Risks

• Quantitative

• Market Sizing, Segmentation and Forecasting

• Market share and Opportunity Analysis

Reporting

• Deliverables

• Whitepapers

• Industry Reports

• Investment Models

• Trend Reports

• Tracking Reports

• Competitive Report

• Price Discovery Report

• Corporate Profiles

• Forecasts

• Guesstimates

• NPV Valuation

• Client Presentation and clarifications on client questions

Assess, Analyze, Derive, Synthesize, Report

19 Lifesciences Catalyst

Select Case Studies

Technology Licensing

Strategic Consulting

Business and Market Research


CaseStudy

Client

Client Need

Solution Approach

Results

**Data has been sanitized and meant for Illustrative purposes only

Exclusive Worldwide Licensing for a Fragrance and Flavors Technology

The University developed an improved process to make Safranal faster, cheaper, and greener.

After patenting it they were finding it difficult to out license it even after more than 2 years of trying .

21

Technology Licensing Office of a reputed University from Chicago area

Aagami deployed a senior consultant to understand and capture important details about the asset / technology

Identified relevant companies in India and elsewhere.

Shortlisted 68 companies and sent them customized ‘Elevator Pitch’ (EP)

After several follow ups on phone calls and emails, coordinated CDAs and conference calls with several interested Companies and brought 3 companies on term sheet level discussions

Aagami supported in structuring and negotiating the deal discussions.

Finally established the partnership within 6 months from the start date

Technology licensing partnerships made with 2 companies in India in 6 months

Client said: “It takes a lot of time and people to pull off an agreement like this, ….. we’re very pleased that we were able to align ourselves with these two reputable international companies.”

http://loyolastudentdispatch.com/2010/11/05/loyola-flavor-and-fragrance-research-goes-global/


http://loyolastudentdispatch.com/2010/11/05/loyola-flavor-and-fragrance-research-goes-global/

CaseStudy

Client

Client Need

Solution Approach

Results


Study of Market Potential and Prospective Partners in India for hand-held qPCR Diagnostic Device

A mobile, lightweight molecular diagnostic technology and device was developed at the University. Its Innovation center wanted to study the market potential in India.

As per Aagami’s suggestion, client agreed to include regulatory overview and potential partners in the study.

22

Innovation Center of a New Zealand University focused on Health Sciences

Aagami involved a team of a senior and a junior researcher to conduct secondary and primary research to assess and collect market data.

Identified Competitors and their product ranges and also did a brief comparison analysis.

Prepared a crisp and concise report with data, analysis and recommendations

Also prepared a regulatory overview document

Captured the potential end users of the product as well as shortlisted potential partners

Offered consulting support for Partnership Development and India Market Entry with a clearly defined Partnering Strategy and roadmap to achieve the goal.

The report helped the University in determining conclusively on India market initiative.

Pleased with the report, the University appointed Aagami to find a licensing partner in India


CaseStudy

Client

Client Need

Solution Approach

Results


Global NPV of Technology (in USD Million)

(P) Pessimistic Scenario

Discount rate 8.60%

Year 2012 2013 2014 2015 2016 2017 2018

Time 0 1 2 3 4 5 6

Revenue from Sale of NPTP POC devices - - 20.30 23.62 32.06 40.80 24.93

Revenue from Sale of Treated Cuvette - - 450.00 614.87 815.48 1,021.15 657.19

Total Cost of NPTP POC devices - - 4.10 5.66 7.69 9.78 5.98

Total Cost of Treated Cuvettes - - 175.00 387.88 514.43 644.17 414.57

Commercialisation Costs 400.00 - - - - - -

Total Cash Inflow - - 470.30 638.49 847.54 1,061.96 682.11

Total cash Outflow 400.00 - 179.10 393.54 522.12 653.96 420.55

Net Cash Flow -400.00 - 291.20 244.95 325.43 408.00 261.56

Discount Factor 1.00 0.92 0.85 0.78 0.72 0.66 0.61

Discounted Cash Flow -400.00 - 246.91 191.24 233.96 270.09 159.44

NPV 1,524.77

Assessment of Global Net Present Value (NPV) of a revolutionary Nanotechnology Based Diagnostic Platform

Client wanted to commercialize ground breaking technology in the MI Diagnostics field, and wanted to know its commercial potential so that suitable licensing fees and model could be determined and also value could be showcased to Licensees

23

Innovative technology company spun out of a University

Aagami involved a team of a senior consultant part time and a business analyst full time to conduct primary and secondary research involving domain specialists to capture current market scenario.

Performed competitive benchmarking to assess a Relative Cost Benefit Index used later for determining technology platform (product) pricing.

Projected annual demand for next ten years in three different scenarios -Median, Optimistic and Pessimistic across multiple disease categories.

Forecasted Global Average Selling Price (ASP) and Cost associated with capex and opex

Validated commercializing options and measured incremental financial scenario for potential licensees

Determined the Global Net Present Value (NPV) and created Financial models

NPV of the technology and indicative licensing fees, along with several insights generated, served as conclusive guidance to the client for deal-making and negotiations.

The client was delighted which also resulted in repeat assignments


CaseStudy

Client

Client Need

Solution Approach

Results


Technology Out-licensing of Transdermal Drug Delivery Technology with 3 Indian Companies

To Out-License TPM® Technology and Co-Develop in clinic products using proprietary Delivery technology and market such products in India and possibly larger region.

24

Technology development Company from Australia

Aagami scanned numerous companies and got 10 relevant companies interested.

Discussion with 8 companies progressed.

Took client to India 3 times for term sheet level meetings and deal signing.

Facilitated entire evaluation and deal structuring process

Aagami made sure testing and other protocols were honoured before deal was made.

During the process Aagami ensured clear understanding despite socio cultural differences in styles of working.

Deals with 3 global companies of India

The first deal was struck for diclofenac topical gel formulation containing TPM platform. The Indian partner not only launched their own product but also out licensed to a major western pharma.

The second alliance was struck for use in Skin Whitening and under eye cream.

Third deal - Aagami was able to facilitate a new business model with this prospect, who using client technology increased bio availability as well as stability of a specific antibiotic.


CaseStudy

Client

Client Need

Solution Approach

Results


Establishing Partnerships for Development and Commercialisation of Novel Class of Protein Drugs

Innovator partners in India to collaborate on a new class of proteins -Anticalins® to develop various programs in Oncology and Ophthalmology.

25

German Biotech company making safer, effective and differentiated Novel drugs

Aagami identified right partners, and took them to 7 interested companies for Anticalins®

With focused efforts 3 companies moved to term sheet level discussions. Aagami kept facilitating and persevering. 2 companies remained for final negotiations.

Aagami maintained its spirits and perseverance knowing Indian ways of working; even when client was ready to give up as per Western ways.

Finally co development partnership happened in next few months with one company in Oncology.

Second company took more time and couple of visits before signing co-development deal for ophthalmic therapy.

Client signed co-development deals with 2 companies in Oct and Dec2013 respectively

Right companies, right advice, structure, perseverance and commitment were the key success factor. in making it happen.

Aagami proved highly influential in negotiations for finalization of the deals due to deep experience in business culture nuances of India.

It brought repeat and referral business to Aagami.


http://aagami.com/news/62-pieris-ag-a-aagami-client-signs-broad-co-development-alliance-for-novel-anticalin-therapeutics-with-zydus-of-india

http://aagami.com/news/64-pieris-ag-a-aagami-client-inks-pact-with-india-s-stelis-biopharma


USA (Head Office)

Aagami, Inc. 2135 City Gate Lane Suite 300

Naperville, IL 60653

P: +1-630-364-1837

INDIA

Aagami

741, Nelson Square

Nagpur MH 440013

P: +91-712-258-6678

Dinesh Jain

Email: [email protected]

M: +1 630-853-3520

Godwyn Francis

Email: [email protected]

M: +91-787-501-6957

www.aagami.com

CONTACT

© Aagami, Inc. 2015 | All rights reserved

Meet us at:

mailto:[email protected]

mailto:[email protected]

http://www.aagami.com/

Aagami Technology Licensing Presentation

Business

Transcript of Aagami Technology Licensing Presentation